drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Afucosylated humanized IgG1κ monoclonal antibody (brand name Fasenra) that binds IL‑5 receptor alpha (IL‑5Rα) on eosinophils and basophils, blocks IL‑5 signaling, and induces antibody‑dependent cell‑mediated cytotoxicity (ADCC), leading to near-complete eosinophil depletion and reduction of type‑2 eosinophilic inflammation in severe eosinophilic asthma.
nci_thesaurus_concept_id
C88594
nci_thesaurus_preferred_term
Benralizumab
nci_thesaurus_definition
An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.
drug_mesh_term
Benralizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Afucosylated humanized IgG1κ monoclonal antibody that binds IL‑5 receptor alpha (IL‑5Rα) on eosinophils and basophils, blocks IL‑5 signaling, and induces potent NK cell–mediated ADCC, leading to near-complete eosinophil depletion and reduction of type‑2 eosinophilic inflammation.
drug_name
Benralizumab
nct_id_drug_ref
NCT05603845